Overview

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

Primary: To demonstrate that PA32540 causes fewer gastric ulcers in subjects at risk for developing aspirin-associated gastric ulcers compared to enteric coated (EC) aspirin 325 mg.

Phase:

Phase 3

Details

Lead Sponsor:

POZEN

Treatments:

Aspirin
Omeprazole